Skip to main content

ETF comparison

IBB vs VHT

Both Healthcare.

iShares Biotechnology ETF · Vanguard Health Care Index Fund ETF Shares

Holdings overlap

Weighted by ISIN/CUSIP
18.9 %

181 positions appear in both funds. Buying equal dollars of IBB and VHT would leave roughly 18.9% of each dollar exposed to the same underlying securities.

IBB unmatched 81.0% Shared 18.9% VHT unmatched 80.9%

Unmatched is the part of a fund's weight the other fund doesn't match: names only it holds, plus any extra weight it puts in names both funds hold.

In IBB only
67 positions
Shared
181 positions
In VHT only
232 positions

Side by side

IBB

iShares Biotechnology ETF

iShares · Healthcare

72 composite / 100
Expense ratio
0.44%
Net assets
$11.50B
TTM yield
0.16%
Top-10 conc.
44.7%
VHT

Vanguard Health Care Index Fund ETF Shares

Vanguard · Healthcare

84 composite / 100
Expense ratio
0.090%
Net assets
$23.73B
whole fund, 2 share classes
TTM yield
1.32%
Top-10 conc.
51.7%

Sub-score comparison

56
Cost
91
85
Tax efficiency
83
100
Liquidity
100
50
Concentration
40
—
Tracking quality
—
IBB sub-score VHT

Tracking quality isn't part of the composite — see what we don't score for why.

Cost difference

VHT is 35 bps cheaper than IBB. On a $100,000 position that's about $350/yr more in fees for IBB.

Fee figure is the annual expense charged on $100,000. To see how the gap compounds over a multi-decade holding period, open the cost calculator pre-filled with IBB vs VHT.

Top shared holdings

181 shared in total
# Holding In IBB In VHT Overlap
1 Amgen, Inc. 7.83% 3.21% 3.21%
2 Gilead Sciences, Inc. 6.84% 2.52% 2.52%
3 Vertex Pharmaceuticals, Inc. 8.08% 1.92% 1.92%
4 Regeneron Pharmaceuticals, Inc. 4.91% 1.15% 1.15%
5 Natera, Inc. 2.89% 0.60% 0.60%
6 Moderna, Inc. 1.98% 0.56% 0.56%
7 Revolution Medicines, Inc. 2.78% 0.46% 0.46%
8 Alnylam Pharmaceuticals, Inc. 3.12% 0.44% 0.44%
9 Illumina, Inc. 2.07% 0.44% 0.44%
10 Biogen, Inc. 2.47% 0.44% 0.44%
11 Insmed, Inc. 1.78% 0.36% 0.36%
12 Incyte Corp. 1.75% 0.29% 0.29%

Only in IBB

67 total
  • Argenx SE 3.76%
  • BeOne Medicines Ltd. 1.77%
  • Ascendis Pharma A/S 1.29%
  • Genmab A/S 1.12%
  • Abivax SA 0.67%
  • BioNTech SE 0.66%
  • Nuvalent, Inc. 0.50%
  • Xenon Pharmaceuticals, Inc. 0.43%
  • CRISPR Therapeutics AG 0.38%
  • Legend Biotech Corp. 0.33%

Only in VHT

232 total
  • Eli Lilly & Co 12.87%
  • Johnson & Johnson 8.75%
  • AbbVie Inc 6.28%
  • Merck & Co Inc 5.06%
  • UnitedHealth Group Inc 4.90%
  • Thermo Fisher Scientific Inc 3.18%
  • Abbott Laboratories 2.66%
  • Pfizer Inc 2.24%
  • Bristol-Myers Squibb Co 1.89%
  • Danaher Corp 1.88%

Percentages are holdings overlap with the named fund.

Open IBB or VHT at a brokerage

Both funds trade commission-free at major US brokerages.

Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.

Holdings overlap is the sum of min(weight_a, weight_b) over positions matched on ISIN (CUSIP fallback). Methodology: see /methodology/.

Comparing two funds doesn't endorse swapping one for the other. Tax-lot history, account type, and personal goals matter — PlainIndex publishes data and methodology, not investment advice.